CH441286A - Verfahren zur Herstellung von Alkenderivaten - Google Patents

Verfahren zur Herstellung von Alkenderivaten

Info

Publication number
CH441286A
CH441286A CH1130363A CH1130363A CH441286A CH 441286 A CH441286 A CH 441286A CH 1130363 A CH1130363 A CH 1130363A CH 1130363 A CH1130363 A CH 1130363A CH 441286 A CH441286 A CH 441286A
Authority
CH
Switzerland
Prior art keywords
preparation
alkene derivatives
alkene
derivatives
Prior art date
Application number
CH1130363A
Other languages
German (de)
English (en)
Inventor
Kennedy Harper Michael John
Nellie Richardson Dora
Leonard Walpole Arthur
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26260578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH441286(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB34989/62A external-priority patent/GB1013907A/en
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of CH441286A publication Critical patent/CH441286A/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/64—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring
    • C07C37/66—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring by conversion of hydroxy groups to O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH1130363A 1962-09-13 1963-09-13 Verfahren zur Herstellung von Alkenderivaten CH441286A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB34989/62A GB1013907A (en) 1962-09-13 1962-09-13 Alkene derivatives
GB30755/65A GB1064629A (en) 1962-09-13 1965-07-20 Alkene derivatives

Publications (1)

Publication Number Publication Date
CH441286A true CH441286A (de) 1967-08-15

Family

ID=26260578

Family Applications (3)

Application Number Title Priority Date Filing Date
CH277067A CH446289A (de) 1962-09-13 1963-09-13 Verfahren zur Herstellung von Alkenderivaten
CH1130363A CH441286A (de) 1962-09-13 1963-09-13 Verfahren zur Herstellung von Alkenderivaten
CH405466A CH538447A (de) 1962-09-13 1966-03-21 Verfahren zur Herstellung der cis- oder trans-Isomeren von Alkenderivaten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CH277067A CH446289A (de) 1962-09-13 1963-09-13 Verfahren zur Herstellung von Alkenderivaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
CH405466A CH538447A (de) 1962-09-13 1966-03-21 Verfahren zur Herstellung der cis- oder trans-Isomeren von Alkenderivaten

Country Status (8)

Country Link
US (1) US4536516A (US06171609-20010109-C00001.png)
BE (2) BE678807A (US06171609-20010109-C00001.png)
BR (2) BR6352734D0 (US06171609-20010109-C00001.png)
CH (3) CH446289A (US06171609-20010109-C00001.png)
DE (1) DE1568834A1 (US06171609-20010109-C00001.png)
DK (3) DK118655B (US06171609-20010109-C00001.png)
FR (1) FR1502607A (US06171609-20010109-C00001.png)
GB (1) GB1064629A (US06171609-20010109-C00001.png)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (US06171609-20010109-C00001.png) * 1962-09-13
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
HU178253B (en) * 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
EP0127128B1 (en) * 1983-05-24 1987-02-25 Bristol-Myers Company Process for the conversion of the e isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen hcl
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4806685A (en) * 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
DE3736682A1 (de) * 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5354861A (en) * 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
ZA944377B (en) * 1993-06-24 1995-12-20 Lilly Co Eli Hypoglycemic agents
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5451590A (en) * 1993-12-21 1995-09-19 Eli Lilly & Co. Methods of inhibiting sexual precocity
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
GB9326255D0 (en) * 1993-12-23 1994-02-23 Roussel Lab Ltd Medical device for the prevention and treatment of cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
NZ272608A (en) 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2243330A1 (en) 1996-01-20 1997-07-24 Ioana Popa Tamoxifen and analogues thereof
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6083990A (en) * 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
JP2001511182A (ja) * 1997-02-09 2001-08-07 ファーモス コーポレイション ステロイドホルモンの永久に荷電された誘導体の増進された抗血管形成誘導活性
EP1011675A1 (en) * 1997-02-27 2000-06-28 PHARMACIA & UPJOHN COMPANY Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
GB9715479D0 (en) * 1997-07-23 1997-10-01 Univ Bradford Tamoxifen and analogues thereof
CA2301032C (en) 1997-08-15 2009-01-13 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1667692A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005084699A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
CA2615374A1 (en) 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101448490A (zh) 2006-05-22 2009-06-03 霍尔莫斯医疗有限公司 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
NZ591955A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for diabetes mellitus type 2
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
CA2861377A1 (en) 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
ES2681023T3 (es) 2012-02-29 2018-09-11 Repros Therapeutics Inc. Terapia de combinación para tratar el déficit de andrógenos
EP3296300B1 (en) 2012-03-05 2019-08-07 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
CN103992234B (zh) * 2014-06-11 2016-05-18 扬子江药业集团江苏海慈生物药业有限公司 一种枸橼酸他莫昔芬e异构体的制备方法
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
WO2018027175A1 (en) 2016-08-04 2018-02-08 University Of Iowa Research Foundation Use of swell1 inhibitors and modulators to treat type 2 diabetes and obesity
JP7100019B2 (ja) 2016-08-19 2022-07-12 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する
RU2020130837A (ru) 2018-02-21 2022-03-21 ЭйАй ТЕРАПЬЮТИКС, ИНК. Комбинационная терапия апилимодом и глутаматергическими агентами
US20220249413A1 (en) * 2019-06-10 2022-08-11 University Of Iowa Research Foundation Swell 1 modulators for treatment of non-alcoholic fatty liver disease, immune deficiencies, male infertility and vascular diseases
CN114133334B (zh) * 2021-11-09 2024-07-19 北京京丰制药(山东)有限公司 枸橼酸他莫昔芬的工业化制备工艺
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4311546A1 (en) 2022-07-26 2024-01-31 Dynacure Combination therapy for myopathies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (US06171609-20010109-C00001.png) * 1962-09-13
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
GB1029221A (en) * 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity

Also Published As

Publication number Publication date
BE678807A (US06171609-20010109-C00001.png) 1966-09-30
DK117953B (da) 1970-06-22
DE1468088A1 (de) 1969-07-31
BE637389A (US06171609-20010109-C00001.png)
BR6678265D0 (pt) 1973-09-18
DK118655B (da) 1970-09-21
DE1568834A1 (de) 1970-11-26
GB1064629A (en) 1967-04-05
US4536516A (en) 1985-08-20
BR6352734D0 (pt) 1973-09-18
FR1502607A (fr) 1967-11-24
DK127777B (da) 1974-01-07
CH538447A (de) 1973-06-30
CH446289A (de) 1967-11-15

Similar Documents

Publication Publication Date Title
CH441286A (de) Verfahren zur Herstellung von Alkenderivaten
CH445514A (de) Verfahren zur Herstellung von 6-Alkylmorphinan-Derivaten
CH430677A (de) Verfahren zur Herstellung von p-Aminoarylaldehyden
CH438350A (de) Verfahren zur Herstellung von 6-Hydroxy-morphinan-Derivaten
AT243794B (de) Verfahren zur Herstellung von Carbostyrilderivaten
AT242863B (de) Verfahren zur Herstellung von α-Amino-arylmethylpenicillinen
CH435303A (de) Verfahren zur Herstellung von 2-Chlor-s-triazinen
AT250582B (de) Verfahren zur Herstellung von 2-Oxa-3-oxo-steroiden
CH427812A (de) Verfahren zur Herstellung von Oxathiazolinonen
CH429729A (de) Verfahren zur Herstellung von Aminoisoxazolen
CH431511A (de) Verfahren zur Herstellung von 1a-Alkylthio-3-keto-steroiden
CH429739A (de) Verfahren zur Herstellung von basisch substituierten Alkylxanthinderivaten
CH475985A (de) Verfahren zur Herstellung von substituierten 2-Oxo-tetrahydrochinolinen
CH460036A (de) Verfahren zur Herstellung von Morphinan-Derivaten
AT241433B (de) Verfahren zur Herstellung von N-Trifluormethyl-N-aryl-aminosulfensäurehalogeniden
CH431518A (de) Verfahren zur Herstellung von 16B-Niederalkylthio-17B-hydroxy-östren-3-onen
CH440265A (de) Verfahren zur Herstellung von 19-Norsteroiden
CH441349A (de) Verfahren zur Herstellung von s-Tetrazinen
CH450443A (de) Verfahren zur Herstellung von Morphinan-Derivaten
AT242149B (de) Verfahren zur Herstellung von 2-Sulfanilamido-5-methoxypyrimidin
AT257064B (de) Verfahren zur Herstellung von 16α-Hydroxysteroiden
CH431510A (de) Verfahren zur Herstellung von Diacylcymarol
CH435302A (de) Verfahren zur Herstellung von 3-Alkoxy-4-nitro-6-alkylpyridazin-1-oxyden
CH441298A (de) Verfahren zur Herstellung von 8B-Methyl-11B-oxysteroiden
CH428750A (de) Verfahren zur Herstellung von N-Trifluormethylaminen